| | | | |
CUSIP No. 36322Q107 | | 13G | | Page 5 of 9 Pages |
Item 1(a). | Name of Issuer: |
Galecto, Inc. (the “Issuer”).
Item 1(b). | Address of Issuer’s Principal Executive Offices: |
75 State Street, Suite 100, Boston, MA 02109.
Item 2. | Name of Person Filing: |
(a) – (c) | Name of Persons Filing; Address; Citizenship |
This statement on Schedule 13(G) is being filed jointly by the following persons, each a “Reporting Person”:
| i. | Sunstone Life Science Ventures Fund III K/S, a Danish limited partnership; |
| ii. | Sunstone LSV General Partner III ApS, a Danish private limited company. Sunstone LSV General Partner III ApS is the general partner of Sunstone Life Science Ventures Fund III K/S; and |
| iii. | Sunstone Life Science Ventures A/S, a Danish public limited liability company. Sunstone Life Science Ventures A/S is the owner of Sunstone LSV General Partner III ApS. |
The principal business address of the Reporting Persons is Store Strandstræde 18, DK-1255 Copenhagen, Denmark.
Item 2(d). | Title of Class of Securities: |
Common Stock, par value $0.00001 per share.
36322Q107
The information set forth in rows 5 through 11 of the cover pages is incorporated herein by reference into this Item 4.
Calculations are based on 25,261,832 shares of Common Stock of the Issuer outstanding as of March 25, 2021, as reported in the Issuer’s annual report on Form 10-K filed with the Securities and Exchange Commission on March 29, 2021.
Item 5. | Ownership of Five Percent or Less of a Class. |
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.